An interventional study of Human albumin infusion at a modified dosage and Human albumin infusion at a routine dosage in Overt Hepatic Encephalopathy, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by General Hospital of Shenyang Military Region · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Hepatic Encephalopathy with a site in China — 16 open to participants now, 18 under way, none of them phase 3. Hepatic Encephalopathy · China.
Among the 26 studies in Hepatic Encephalopathy with a site in China, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2025, is one of 11 with no phase, reaches primary completion later than 7 of the 17 other live ones, and was the 13th registered.
225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.
Browse Hepatic Encephalopathy studies →16 of the 26 studies in Hepatic Encephalopathy with a site in China are open now. Recruiting first, the newest first:
Air Force Military Medical University, China · Sites in China
Ages 18+
Air Force Military Medical University, China · Sites in China
Ages 18–75 · Healthy volunteers
Air Force Military Medical University, China · Sites in China
Ages 18–75
The Second Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–75
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 1 · Phase 4 2
First in 2014; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 174 is above the median of 60 across 154 interventional studies indexed under Hepatic Encephalopathy.
Median enrollment 100 across the 17 interventional studies, 252 across the 9 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 26 has an industry lead sponsor. The 10 most frequent:
General Hospital of Shenyang Military Region is the lead sponsor of 78 studies on the registry; 33 are open to participants now.
General Hospital of Shenyang Military Region has 1 study filed under Hepatic Encephalopathy — fewer than ten, so there is no comparison to draw.
4 of the studies in Hepatic Encephalopathy with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07683936Air Force Military Medical University, ChinaFecal Microbiota Transplantation for the Treatment of Refractory Hepatic Encephalopathy After TIPS Surgery | 2027-01-31 |
| NCT07273734West China HospitalUDCA to Prevent Post-TIPS Hepatic Encephalopathy | 2027-06-30 |
| NCT06483737General Hospital of Shenyang Military RegionHuman Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) | 2027-06-30 |
| NCT07852416The First Affiliated Hospital with Nanjing Medical UniversityElectronic PHES vs Paper-based PHES for Hepatic Encephalopathy | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 26 studies in Hepatic Encephalopathy with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human albumin infusion at different dosages in in patients with liver cirrhosis and overt HE.
Overall, 174 patients with a diagnosis of liver cirrhosis, overt HE, and a serum albumin level of 23-30g/L will be enrolled. They will be stratified according to the severity of overt HE and randomly assigned at a ratio of 1:1 into the groups of human albumin infusion at a modified dosage and a routine dosage. The primary endpoint is the improvement of overt HE within 3-5 days after treatment. The secondary endpoints include recurrence of overt HE, survival, and adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous infusion of human albumin 30-60g.
Drug: Human albumin infusion at a modified dosage · Drug: Lactulose · Drug: Rifaximin · Drug: Ornithine Aspartate · Drug: Branched-Chain Amino Acids · Drug: Arginine
Intravenous infusion of human albumin 10-20g.
Drug: Human albumin infusion at a routine dosage · Drug: Lactulose · Drug: Rifaximin · Drug: Ornithine Aspartate · Drug: Branched-Chain Amino Acids · Drug: Arginine
Participants receive intravenous infusion of human albumin at different dosages according to the serum albumin level.
Also known as: AlbuRx
Participants receive intravenous infusion of human albumin according to the current clinical practice.
Also known as: AlbuRx
All participants will receive standard treatment of overt HE according to the current practice guideline.
Also known as: Duphalac
All participants will receive standard treatment of overt HE according to the current practice guideline.
Also known as: Xifaxan
All participants will receive standard treatment of overt HE according to the current practice guideline.
All participants will receive standard treatment of overt HE according to the current practice guideline.
Also known as: Compound amino acid injection
All participants will receive standard treatment of overt HE according to the current practice guideline.
Also known as: Arginine Hydrochloride Injection
Change of overt HE.
The change of HE is defined as a decrease or an increase of at least one grade of the West Haven criteria after treatment.
Time frame: 3-5 days
Reversal of overt HE.
The reversal of HE is defined as clinical symptoms of overt HE disappear after treatment.
Time frame: 3-5 days
Recurrence of overt HE.
Clinical symptoms related to overt HE recur and can be diagnosed with overt HE again according to the West Haven criteria.
Time frame: 3 months
Adverse events
Adverse events will be monitored, including allergy, heart failure, pulmonary edema, acute hemolysis, renal dysfunction, and neuropsychiatric abnormalities.
Time frame: 3 months
Survival
All participants will be followed by telephone to record survival status, including the major cause and date of death.
Time frame: 3 months
Plan to share: No
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.
Of 26 interventional studies with no phase under Hepatic Encephalopathy, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 72. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
General Hospital of Shenyang Military Region